Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Barinthus Biotherapeutics (BRNS – Research Report). The associated price target remains the same with $3.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen has given his Buy rating due to a combination of factors including Barinthus Biotherapeutics’ strategic focus on immunology and inflammation, particularly the development of VTP-1000 for celiac disease. The company is progressing with its Phase 1 AVALON trial, which is expected to yield data in the third quarter of 2025. This trial is significant as it evaluates the potential of VTP-1000, an innovative antigen-specific tolerance immunotherapy, to promote immune tolerance to gluten through a novel delivery method.
Additionally, the positive outcomes from the Phase 2 trials of VTP-300 in chronic hepatitis B further support the Buy rating. The promising results, including functional cures and seroconversions, highlight the potential of Barinthus’ pipeline. Furthermore, with a strong cash position projected to sustain operations into 2027, the company is well-positioned financially to advance its clinical programs and explore strategic partnerships.
Chen covers the Healthcare sector, focusing on stocks such as Opko Health, Vivani Medical, and OKYO Pharma Limited Sponsored ADR. According to TipRanks, Chen has an average return of -16.4% and a 29.18% success rate on recommended stocks.